AMSTERDAM, June 23, 2025 /PRNewswire/ -- On June 18–19, the Global Dairy Congress 2025 was held in Amsterdam. At the forum, Dr. Ignatius Szeto, Assistant President of Yili Group, delivered a keynote speech titled "Innovating for a sustainable future" and shared Yili's latest innovative practices.
On the opening day, the organizers unveiled the winners of the 2025 World Dairy Innovation Awards. Yili secured four World Dairy Innovation Awards and six commended Awards. Notably, Yili has claimed the World Dairy Innovation Awards for six consecutive years.
Dr. Carolien van Loo, Head of Yili Innovation Center Europe, attended a roundtable forum on maternal and infant nutrition and breast milk research. Multiple star products from Yili's top infant formula brand, Pro-Kido, were featured as the Congress's officially designated products.
At the Industry Leadership Forum, Dr. Ignatius Szeto systematically introduced Yili's global innovation practices across product innovation, maternal and infant nutrition, advanced dairy processing, and sustainable development. He emphasized: "Innovation is the driving force behind the sustainable prosperity of the dairy industry. Remaining consumer-centric, Yili dedicates itself to nutrition and health research across the full life cycle, keeps making core technological breakthroughs, and accelerates the commercialization of fundamental research outcomes—all of which contribute to the advancement of the global dairy sector."
During the roundtable forum themed "Innovation in Pioneering a New Future for Global Maternal and Infant Health", Dr. Ignatius Szeto and Dr. Carolien van Loo engaged in in-depth discussions with experts including Jean-Christophe Kremer, Secretary-General of the International Special Dietary Foods Industries, and Richard Hall, Chair of FoodBev Media. The discussions focused on research about breast milk and maternal and infant nutrition. Dr. Carolien van Loo highlighted that Yili Innovation Center Europe, in collaboration with institutions such as Wageningen University and Donders Institute for Brain, Cognition and Behaviour, has conducted pioneering research on HMOs. Their breakthrough findings demonstrated HMOs' health benefits in enhancing immunity, protecting gut barrier function, preventing pathogen adhesion, and promoting cognitive development.
The annual World Dairy Innovation Awards were announced at the event. This year, Yili Group secured four awards for its high-quality products and outstanding performance in innovation. Zhenlao Light Cream from Yijiahao Cheese won the Best Artisan Product, Joyday Crunchy Choco Lava was awarded Best Ice Cream, Yili's patented multi-enzymatic lactose-to-GOS technology: Boosting Gut Health in Qinghuo Adult Milk Powder claimed the Best Intolerance-Friendly Innovation, and Satine Carbon-Reduced Organic Milk won the Best CSR/Sustainability Initiative.
Staying true to its philosophy of "No Innovation, No Future," Yili consistently increases its R&D investment to provide comprehensive nutrition solutions for consumers across the full life cycle. To date, Yili has established 15 innovation centers across Asia, Europe, and Oceania.
Moving forward, Yili will continue to align its strategy with consumer needs, drive growth through technological innovation, and foster global partnerships to deliver enhanced health value for consumers worldwide, aiming to enable the sustainable prosperity of the dairy industry.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Yili Secures Four World Dairy Innovation Awards at the 18th Global Dairy Congress
Yili Secures Four World Dairy Innovation Awards at the 18th Global Dairy Congress
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
